Bank of America’s NRX Pharmaceuticals NRXP Stock Holding History

Bank of America’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,810	Closed	-$168K	–	8503
2021 Q3	$168K	Buy	+1,810	New	+$235K	﹤0.01%	6420

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Bank of America's NRXP Position: Q1 2026 in Review

Bank of America sold out of NRX Pharmaceuticals (NRXP) in Q1 2026, closing a stake of 3,239 shares — an estimated $8.78K sold.

Bank of America first reported a position in NRXP in Q3 2021 and held it in 16 quarters. The position peaked at $179K in Q3 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

Bank of America reported no remaining NRX Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bank of America sold 3,239 NRX Pharmaceuticals shares in Q1 2026, an estimated $8.78K.
Bank of America first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 16 quarters.
Bank of America's NRX Pharmaceuticals position peaked at $179K in Q3 2021.
33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.